SCHEMBL828266

SCHEMBL828266

N#Cc1ccccc1CN1CCOCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 5/20 0.58
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
ALDH1A1 P00352 5/20 0.50
HSD17B10 Q99714 2/20 0.50
CYP2C9 P11712 2/20 0.50
ALOX15 P16050 1/20 0.50
KDM4E B2RXH2 3/20 0.48
HPGD P15428 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP19A1 P11511 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
COMT P21964 1/20 0.45
CXCR4 P61073 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28024574 0.88 COMT (0.53) KMT2AALDH1A1MAPTCYP19A1SMN1; SMN2
SCHEMBL20804350 0.88 COMT (0.53) KMT2AALDH1A1MAPTCYP19A1SMN1; SMN2
SCHEMBL20237949 0.84 CYP19A1 (0.50) ALDH1A1KDM4EMAPTCYP19A1SMN1; SMN2
SCHEMBL2229998 0.84 ALDH1A1 (0.53) ALDH1A1HSD17B10KDM4EMAPTCYP19A1
SCHEMBL7343956 0.83 CYP2A13 (0.58) CYP2A13KMT2AMEN1ALDH1A1HSD17B10
SCHEMBL519226 0.83 ALDH1A1 (0.56) ALDH1A1HSD17B10KDM4EMAPTLMNA
SCHEMBL2229808 0.83 ALDH1A1 (0.56) ALDH1A1HSD17B10KDM4EMAPTLMNA
SCHEMBL11193326 0.82 CYP2A13 (0.75) CYP2A13KMT2AMEN1ALDH1A1HSD17B10
SCHEMBL20381979 0.80 KMT2A (0.60) KMT2AALDH1A1MAPTCYP19A1SMN1; SMN2
SCHEMBL22642414 0.80 COMT (0.48) KMT2AALDH1A1MAPTCYP19A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550135-B2 Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-02-04 US claimed
WO-2014004863-A2 COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) 2014-01-03 WO claimed
EP-2563143-A1 SUBSTITUTED 1,3-BENZOTHIAZOL-2(3H)-ONES AND [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 Merck Sharp & Dohme Corp. (US) 2013-03-06 EP claimed
WO-2011137046-A1 SUBSTITUTED 1,3-BENZOTHIAZOL-2(3H)-ONES AND [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME CORP. (US) 2011-11-03 WO claimed
CN-106459044-A Tank-binding kinase inhibitor compounds 吉利德科学公司 2017-02-22 CN disclosed
US-9469710-B2 Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORPORATION (JP) 2016-10-18 US disclosed
EP-2183259-B1 PARACYCLOPHANE-BASED LIGANDS, THEIR PREPARATION AND USE IN CATALYSIS JOHNSON MATTHEY PLC (GB) 2015-10-21 EP disclosed
CN-103025816-B Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORP 2015-07-22 CN disclosed
US-20150148489-A1 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2015-05-28 US disclosed
CN-103025816-A Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORP 2013-04-03 CN disclosed
US-20120296041-A1 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2012-11-22 US disclosed
EP-1724262-B1 1-(2H)-ISOQUINOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2012-05-02 EP disclosed
US-8143274-B2 1-(2H)-isoquinolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-03-27 US disclosed
EP-2382240-A2 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP Bridgestone Corporation (JP) 2011-11-02 EP disclosed
WO-2011091346-A2 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2011-07-28 WO disclosed
WO-2010085622-A9 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2010-12-23 WO disclosed
WO-2010085622-A2 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2010-07-29 WO disclosed
US-20070185160-A1 1-(2H)-isoquinolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-08-09 US disclosed
EP-1724262-A1 1-(2H)-ISOQUINOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550135-B2 Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity SMS, H1-5, SRM CYP2A13 2328/4885KMT2A 608/4885MEN1 206/4885
US-20070185160-A1 1-(2H)-isoquinolone derivative NR3C2, NR1H4, NR3C1 CYP2A13 89/4885KMT2A 3020/4885MEN1 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.